Grounded in a portfolio of in-licensed technologies from the University of Missouri and Clemson University, Organovo’s bioprinting technology has fostered the development of a wide variety of applications. The following selected publications highlight the capabilities of the bioprinting platform:
Modeling Compound-Induced Fibrogenesis In Vitro Using Three-Dimensional Bioprinted Human Liver TissuesPresenter: Leah Norona, Doctoral Candidate at UNC Chapel Hill Date/Time: Thursday, July 28th, 2016 at 10 am ET / 4 pm CET
Use of Bioprinted 3D Human Tissues for the Assessment of Drug ToxicityPresented by Sharon Presnell, Ph.D., Chief Scientific Officer, Organovo
June 30, 2016.